Lv4
518 积分 2024-07-24 加入
Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023
2天前
已完结
Decoding the Implications of Glucagon-Like Peptide-1 Receptor Agonists on Accelerated Facial and Skin Aging
2天前
已完结
Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study
2天前
已完结
Glucagon-Like Peptide-1 Receptor Agonist Medications and Hair Loss: A Retrospective Cohort Study
2天前
已关闭
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
4天前
已完结
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and MultipleAscending Dose Study of AMG 133 in Subjects with Obesity
5天前
已完结
Non‐clinical and first‐in‐human characterization of ECC5004/AZD5004, a novel once‐daily, oral small‐molecule GLP‐1 receptor agonist
6天前
已完结
Safety, pharmacokinetics and pharmacodynamics of HRS‐7535, a novel oral small molecule glucagon‐like peptide‐1 receptor agonist, in healthy participants: A phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, and food effect trial
6天前
已完结
Safety, pharmacokinetics and pharmacodynamics of multiple‐dose noiiglutide (SHR20004), a novel GLP‐1 receptor agonist, in Chinese obese subjects without diabetes mellitus
7天前
已完结
Tirzepatide for Obesity Treatment and Diabetes Prevention
9天前
已关闭
皖公网安备34019202002308
